reference pa	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion
Analgesia and   - I     pulmonary function after   end     lung surgery: is a single   - a     intercostal nerve block   - a     plus patient-controlled   m     epidural anaesthesia? A   - a     randomized non-   - a     inferiority clinical trial.   Br J Anaesth.     2011;106(4):580-9.   a     dd   - a     gr   - a <tr< td=""><td>age &lt;18 yrs any contraindication to TEA, intercostal lerve block, or to the use of ropivacaine, morphine, metamizole, or diclofenac inability to understand the pain scale or to berform a spirometry any type of chronic painful condition or current opioid use <b>lemographic data:</b> group E group I ex (f/m) 12/33 9/34 ge (yrs) 64 (24-74) 65 (28–87) leight (cm) 174 (158-190) 170 (155–188) veight (kg) 75 (56-108) 76 (52–107) NSA physical status (I/II/III/IV) 1/6/36/1 2/8/33/0 vatient flow and follow up: otal patient number included:</td><td>mode of anaesthesia - fentanyl surgical approach (n) E I pneumonectomy 2 6 bilobectomy 2 2 lobectomy 17 16 segmentectomy or wedge resection 24 19 at the end of surgery - group E (TEA): ropivacaine 1% (8 mL) initially then ropivacaine 1% (5 mL) repeated every 60 min - group I (ICB): a total of 30 mL ropivacaine 0.75% (225 mg) injected before chest closure supplemental analgesia - oral diclofenac 75 mg every 12 h + IV metamizole 1 g every 6 h for 4 days postop - IV morphine as rescue analgesia postoperative analgesia - group E: PCEA with 0.2% ropivacaine + sufentanil (2 mg/mL), 3 mL bolus doses with 15 min lo - group I: morphine PCA 2 mg bolus, 15 min lo</td><td><b>postoperative pain [NRS]: median (95% CI)</b> - median treatment differences regarding pain scores at rest failed to demonstrate non-inferiority of the intercostal nerve block at the first postoperative day. - patients of the intercostal group reported significantly higher pain scores on coughing during the first and second postoperative days total dosage of fentanyl/remifentanil [mg]: median (range) group E group I p - fentanyl (mg) 0.5 (0.4–1.0) 1.1 (0.5–2.0) 0.001 - remifentanil (mg) 0.8 (0.0–2.7) 1.5 (0.3–3.9) 0.003: pulmonary outcomes - there was a trend to a better preserved pulmonary function in the group E, but was not statistically significant adverse effects/ events - no significant differences in nausea, vomiting or pruritis between the groups</td><td>methodological shortcomings - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups - not reported whether the sequence was adequately concealed until interventions were assigned - dates defining the period of recruitment and follow-up not reported level of evidence: 1 authors' conclusion "In patients undergoing lung surgery, single intercostal nerve block plus IV PCA with morphine is not as effective as patient-controlled TEA with respect to pain control and restoration of pulmonary function."</td></tr<>	age <18 yrs any contraindication to TEA, intercostal lerve block, or to the use of ropivacaine, morphine, metamizole, or diclofenac inability to understand the pain scale or to berform a spirometry any type of chronic painful condition or current opioid use <b>lemographic data:</b> group E group I ex (f/m) 12/33 9/34 ge (yrs) 64 (24-74) 65 (28–87) leight (cm) 174 (158-190) 170 (155–188) veight (kg) 75 (56-108) 76 (52–107) NSA physical status (I/II/III/IV) 1/6/36/1 2/8/33/0 vatient flow and follow up: otal patient number included:	mode of anaesthesia - fentanyl surgical approach (n) E I pneumonectomy 2 6 bilobectomy 2 2 lobectomy 17 16 segmentectomy or wedge resection 24 19 at the end of surgery - group E (TEA): ropivacaine 1% (8 mL) initially then ropivacaine 1% (5 mL) repeated every 60 min - group I (ICB): a total of 30 mL ropivacaine 0.75% (225 mg) injected before chest closure supplemental analgesia - oral diclofenac 75 mg every 12 h + IV metamizole 1 g every 6 h for 4 days postop - IV morphine as rescue analgesia postoperative analgesia - group E: PCEA with 0.2% ropivacaine + sufentanil (2 mg/mL), 3 mL bolus doses with 15 min lo - group I: morphine PCA 2 mg bolus, 15 min lo	<b>postoperative pain [NRS]: median (95% CI)</b> - median treatment differences regarding pain scores at rest failed to demonstrate non-inferiority of the intercostal nerve block at the first postoperative day. - patients of the intercostal group reported significantly higher pain scores on coughing during the first and second postoperative days total dosage of fentanyl/remifentanil [mg]: median (range) group E group I p - fentanyl (mg) 0.5 (0.4–1.0) 1.1 (0.5–2.0) 0.001 - remifentanil (mg) 0.8 (0.0–2.7) 1.5 (0.3–3.9) 0.003: pulmonary outcomes - there was a trend to a better preserved pulmonary function in the group E, but was not statistically significant adverse effects/ events - no significant differences in nausea, vomiting or pruritis between the groups	methodological shortcomings - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups - not reported whether the sequence was adequately concealed until interventions were assigned - dates defining the period of recruitment and follow-up not reported level of evidence: 1 authors' conclusion "In patients undergoing lung surgery, single intercostal nerve block plus IV PCA with morphine is not as effective as patient-controlled TEA with respect to pain control and restoration of pulmonary function."